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NordiQC Assessments of Keratin 5 Immunoassays
Christian Thomsen, MD,* Ole Nielsen, HT,† Søren Nielsen, HT,* Rasmus Røge, MD,*‡
and Mogens Vyberg, MD*‡
Abstract: This paper is number 7 in a series developed through a
partnership between ISIMM and NordiQC with the purpose of
reporting research assessing the performance characteristics of
immunoassays in an external proficiency testing program.
Key Words: keratin 5, cytokeratin 5, immunohistochemistry,
NordiQC, external quality assurance
(Appl Immunohistochem Mol Morphol 2020;28:566–570)
KEY POINTS FOR K5 IMMUNOASSAYS
 The mouse monoclonal (mm) antibody (Ab) clone
XM26 is recommendable.
 The rabbit monoclonal (rm) Ab clones BSR55 and
EP24 are promising.
 The rmAb clone SP27 has a superior analytical
sensitivity, but unexpected reactions in lung adenocar-
cinomas have been observed for this clone, which can
potentially cause diagnostic problems.
 The mmAb clone D5/16 B4 cannot be recommended
due to an inferior analytical sensitivity and the risk of a
false-positive reaction [mouse ascites Golgi (MAG)].
 For laboratory-developed assays, use an optimized protocol
based on carefully calibrated Ab titer, efficient heat-induced
epitope retrieval (HIER) in an alkaline buffer, and a
sensitive 3-step polymer/multimer-based detection system.
 Use the pancreas, tonsil, and liver as positive and
negative tissue controls.
INTRODUCTION
Keratins (Ks) are a subgroup of intermediate filaments
that constitute an essential part of the cytoskeleton of all
mammalian epithelial cells. In humans, there are at least 54
functional K genes, of which about half are expressed in epi-
thelial cells, following a highly specific pattern according to the
epithelial type, location, and level of differentiation. The Ks are
grouped as either acidic (type I) or basic-to-neutral (type II).
A pair of K molecules (one type I and one type II) forms an
obligatory heterodimer, which subsequently polymerizes to
form a filament.1 The most clinically relevant type II filaments
are numbered K1-8 according to decreasing molecular weight
(MW) from 68 to 52.5 kDa, whereas the type I Ks are num-
bered K9-20, also with decreasing MW from 64 to 40 kDa.2,3
For practical purposes, the Ks can be further grouped ac-
cording to MW as either low molecular weight (LMW; K7-8
and K17-20) or high MW (HMW; K1-6 and K9-16). The
LMW-Ks are mainly expressed in simple (single layered) epi-
thelia and the superficial cells of complex (2-layered) epithelia.
HMW-Ks are primarily expressed in complex, squamous, and
transitional epithelia, with K5 being the most abundant and
clinically relevant, usually paired with K14. In complex epi-
thelia (eg, bronchi, breast, prostate), K5 is expressed in basal/
myoepithelial cells, and in squamous and transitional epithelia,
K5 is expressed in all layers, strongest in the basal and
suprabasal.1,4
In surgical pathology, immunohistochemical (IHC)
demonstration of K5 is used for multiple purposes, for ex-
ample, identification of squamous cell differentiation in
primary neoplasia and metastasis of unknown origin, as
neoplastic epithelial cells tend to retain the K expression
profile of the epithelium that they originate from.1,4 Also, K5
is used in the distinction between usual ductal hyperplasia
and atypical ductal hyperplasia of the breast because usual
ductal hyperplasia contains K5 positive myoepithelial cells
admixed with ductal cells, which is not the case in atypical
ductal hyperplasia.5 Both in the breast and in the prostate,
invasive epithelial neoplasias can be separated from non-
invasive lesions by the loss of K5-positive basal cells.5,6
During 2004 to 2019, the Nordic immunohistochemical
Quality Control (NordiQC) program assessed IHC assays for
HMW-K 7 times. Four of these assessments (runs) were based
on HMW-K without further specification (2006, 2008, 2011,
and 2013) and 3 were based on K5 (2004, 2016, and 2019).
The aim of this paper is to present an overview of the external
quality assessment results of K5 immunoassays by presenting
the results from the latest NordiQC runs.
MATERIALS AND METHODS
NordiQC have accomplished 7 runs for HMW-K
and K5. This paper will focus on the 2 most recent runs
(46 and 55), which only included assays for K5.
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A complete description of the assessment proce-
dures is available on NordiQC’s website (www.nordiqc.
org) and in a review.7 In brief, unstained slides from a
tissue micro array (TMA) containing 5 to 7 cores of
diagnostically relevant normal and neoplastic tissues are
distributed to the participating laboratories (Labs). The
Labs then stain the slides, using their routine protocol
for K5, and return them to NordiQC for evaluation. In
preparation of the assessment, 3 sections from different
levels of each TMA are stained at the NordiQC refer-
ence Lab to monitor and validate the K5 expression
levels in the material circulated. A panel of experienced
pathologists and technicians assess the anonymized
slides from the participating Labs, assigning a score of
either “optimal,” “good,” “borderline,” or “poor.” The
optimal and good stains are considered sufficient for
diagnostic use. To participate in the NordiQC assess-
ment, Labs submit comprehensive data on the protocol
settings applied with detailed information on, for ex-
ample, staining platform, epitope retrieval, antibody
clone and format, incubation conditions, and detection
system. This enables NordiQC to provide feedback and
recommendations on protocol settings providing opti-
mal results, both directly to the individual Lab in case of
an insufficient result, and through publications on the
website, www.nordiqc.org. The TMAs for K5 in run 46
and run 55 both comprised prostate hyperplasia, lung
adenocarcinoma, and 2 lung squamous cell carcinomas.
In addition, run 46 also included the esophagus, whereas
the tonsil, liver, and pancreas were included in run
55. The following staining patterns were considered
optimal:
 A strong and distinct cytoplasmic staining reaction of
the majority of basal cells in the hyperplastic prostate
glands.
 A moderate to strong and distinct, cytoplasmic staining
reaction in almost all squamous epithelial cells in the tonsil.
 A moderate to strong and distinct cytoplasmic staining
reaction of all squamous epithelial cells in the esophagus
throughout all the cell layers.
 At least a weak to moderate cytoplasmic staining
reaction of the majority of neoplastic cells in one of the
lung squamous cell carcinomas in run 46, and a
moderate to strong cytoplasmic staining reaction of
almost all neoplastic cells in the other lung squamous cell
carcinomas.
 A weak to moderate, predominantly membranous
staining reaction of scattered cuboidal epithelial cells
in the pancreatic intercalated ducts.
 No staining of neoplastic cells in the lung adenocarcinomas.
 No staining reaction in the liver.
RESULTS
In total, 529 K5 stained slides were submitted in run
46 (n= 266) and run 55 (n= 263). The proportions of
sufficient results (scored optimal or good) were 68% in run
46 and 44% in run 55, respectively. The corresponding
proportions of optimal results were 33% and 25%, re-
spectively. In both runs, the large majority of insufficient
results were due to weak or false-negative staining re-
actions (Fig. 1). In the remaining insufficient results, false-
positive staining reactions were seen.
An overview of the performance of the most com-
monly used Ab clones in the 2 runs is presented in Table 1.
The number of different Ab clones used by the
participating Labs was 7 in run 46 and 8 in run 55, either
as concentrates (Conc) or as ready to use (RTU) products.
A few of them were available as K5/K14 Ab-cocktails. In
the following, each Ab clone will be described separately,
except those that were only represented in run 46. The
results for the RTU products based on the same Ab clone
are pooled.
In both runs, the majority of assays were based on
the mmAb clone D5/16 B4, accounting for 66% in run 46
and 61% in run 55, respectively. In run 46, 63% (55/88) of
assays based on Conc from several vendors were suffi-
cient, whereas only 25% (14/55) were sufficient in run 55.
Similar results were seen for assays based on RTU
products. In run 46, 57% (50/87) of the assays were suf-
ficient, but only 21% (22/105) of the assays were sufficient
in run 55. None of the Labs that obtained optimal results
with an RTU product in run 55 used the protocol settings
provided by the vendor, but used Lab optimized protocol
settings or staining platform other than that intended by
the vendor. The reasons for insufficient results were low
analytical sensitivity and, in some cases, a false-positive
reaction [probably caused by MAG reaction, which can
be seen in tissue from persons with blood type A
(Fig. 1)].8,9 Different vendors use either ascites or
supernatant-based Ab production for clone D5/16 B4.
Overall, the supernatant formats performed better than
the ascites formats, as the MAG reaction is only seen
with the latter.
Another commonly used clone was mmAb XM26,
which performed rather uniformly in the 2 runs. Used as a
Conc, 77% (40/52) of the Labs achieved a sufficient result
in run 46, and 77% (41/53) were sufficient in run 55. Three
of 3 protocols based on XM26 RTU products in run 46
were sufficient. In run 55, 89% (8/9) were sufficient.
In both runs, a cocktail of the mmAb clones XM26
and LL002 (against K14) was used by a few Labs. The
results were not better than for XM26 used alone.
The rmAb clone EP1601Y performed well in run
46, when used as a Conc. All 9 were sufficient. This is in
contrast to the performance in run 55, where only 1 of 6
was sufficient. The same negative tendency was seen for
the few RTU-based protocols with this clone. Most of the
insufficient results were due to a weak or false-negative
reaction.
The rmAb clone SP27 showed superior performance
in both runs. The Labs that used Concs (4 in total) all
achieved an optimal score. All 18 assays in run 55 based
on the RTU SP27 760-4935 were sufficient.
The rmAb clones BSR55 (Conc) and EP24 (Conc or
RTU) were only represented in run 55, and only used by
1 and 2 Labs, respectively, all producing an optimal result.
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DISCUSSION
Most insufficient results in both runs 46 and 55 were
characterized by a too weak or even false-negative re-
action in cells that were expected to be positive. In general,
protocols with optimal results were based on efficient
HIER (preferable in an alkaline buffer), a well-calibrated
primary Ab concentration, and a sensitive detection sys-
tem (preferably a 3-step polymer/multimer-based system).
The proportion of sufficient results was critically low
(44%) in run 55 (2019), and much lower compared with run
46 (2016). Pancreatic tissue was included in the TMA for
run 55 only. The pancreas is recommended by the Inter-
national Ad Hoc Expert Committee as a low expressing on-
slide external tissue control, with an expected weak to
moderate, predominantly membranous staining reaction of
scattered epithelial cells in the intercalated ducts.10 This
places high demands on the K5 IHC assays, and is probably
one of the main reasons for the high proportion of in-
sufficient results in run 55. Other recommendable controls
are the tonsil, which should show a moderate to strong and
distinct, cytoplasmic reaction for K5 in almost all squamous
epithelial cells, and the liver, which should be negative.
The majority of Labs that participated in NordiQC as-
sessments of K5 used assays based on the mmAb clone D5/16
B4. This clone has an inferior analytical sensitivity compared
with the other established clones, such as XM26 and SP27.
In addition to a low analytical sensitivity with a risk of false-
negative results, examples with false-positive reactions were
also seen, probably due to the MAG reaction. Although a few
optimal results were seen in run 55, clone D5/16 B4 is chal-
lenging, and the chance of obtaining a reliable result is better
with one of the more robust alternatives, which are available
for all the major stainer platforms.
A high proportion of optimal results was obtained
by assays based on the mmAb clone XM26 and the rmAb
clones BSR55, EP24, and SP27. However, the data on
BSR55 and EP24 are limited. In a recent study by Nor-
diQC, SP27 produced a distinct positive reaction in 23%
(14/62) of lung adenocarcinomas that could not be dem-
onstrated by other K5 Abs or p40 (unpublished data). In
another Lab, unexpected positive reaction by SP27 was
observed in 1 of 9 lung adenocarcinomas and 1 of 9 col-
orectal adenocarcinomas that were both XM26 negative
(unpublished data). This phenomenon can potentially
cause diagnostic problems, especially if SP27 is used for
the characterization of non–small cell lung cancer.
As mentioned above, the latest runs only included
Ab clones against K5. In the earlier runs with HMW-K
without further specification, the mmAb clone 34βE12
was commonly used, which targets a range of HMW-Ks.
A large proportion of insufficient results with 34βE12
was demonstrated, often due to a false-positive reaction
FIGURE 1. Comparison of sufficient (left column) and insufficient K5 immunohistochemical assays (right column). A, Tonsil with
optimal K5 staining result with a protocol based on mouse monoclonal antibody clone XM26. There is a strong staining of almost
all squamous epithelial cells. B, Tonsil with a too weak staining due to an insufficient protocol based on D5/16 B4. The reaction in
the squamous epithelium is weaker than that seen in (A), but the epithelial cells are still clearly marked. C, Demonstration of basal
cells in prostate hyperplasia using the same protocol as in (A). A strong and distinct reaction is seen in almost all basal cells. D,
Insufficient K5 staining of prostate hyperplasia using the same protocol as in (B). There is only a weak to moderate staining reaction
in the basal cells. Using this protocol for prostatic neoplastic lesions could potentially cause diagnostic difficulties. E, Demonstration
of K5 in the pancreas using the same protocol as in (A). Scattered cuboidal epithelial cells of intercalated ducts show a weak to
moderate predominantly membranous staining reaction. F, False-negative reaction in the pancreas with the same protocol as in
(B). Inset: same core as in (F) showing a false-positive perinuclear reaction (mouse ascites Golgi reaction) in acinar cells of the
pancreas with a protocol based on monoclonal antibody D5/16 B4 (Dako, M7237). In addition, the staining is false negative, as
there is no marking of the intercalated ducts. All photos are from slides scanned at 200×.
TABLE 1. Staining Results for the Most Commonly Used (>5 participants) Antibody Clones in the 2 Latest Assessments of Keratin
5 by NordiQC
Run 46 (2016) Run 55 (2019)
Clone, Concentrate* No. Slides Optimal (%) Good (%) Insufficient (%) No. Slides Optimal (%) Good (%) Insufficient (%)
mmAb D5/16 B4 88 24 39 38 55 7 18 75
mmAb XM26 52 48 29 23 53 60 17 23
rmAb EP1601Y 9 67 33 0 6 0 17 83
Clone, ready to use
mmAb D5/16 B4 IR/IS780 36 3 22 75 25 4 8 88
mmAb D5/16 B4 GA780 11 9 73 18 21 0 5 95
mmAb D5/16 B4 790-4554 38 39 39 21 56 7 25 68
rmAb SP27 760-4935 12 92 0 8 18 83 17 0
mmAb XM26 PA0468 — — — — 8 50 38 12
*The results for the concentrates are pooled from several vendors.
mmAb indicates mouse monoclonal antibody; rmAb, rabbit monoclonal antibody.
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(presumably cross reaction with an LMW-K).11 It was
repeatedly concluded by NordiQC that 34βE12 could not
be recommended for the demonstration of HMW-K.
A more comprehensive description of the results and
optimal protocol settings can be found in the assessment
reports at www.nordiqc.org.12
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